Philip A. Pizzo, M.D.

Publication Details

  • Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens CYTOKINE Roilides, E., Lyman, C. A., Mertins, S. D., Cole, D. J., Venzon, D., Pizzo, P. A., Chanock, S. J., Walsh, T. J. 1996; 8 (1): 42-48

    Abstract:

    The ex vivo effects of macrophage colony-stimulating factor (M-CSF) on antifungal and antibacterial activities of human elutriated monocytes were studied. Cells were isolated prior to the initiation of therapy, on day 3 and at week 7, in six patients with an advanced malignancy receiving M-CSF in a phase I study. Superoxide anion production by monocytes in response to N-formyl methionyl leucyl phenylalanine was enhanced at day 3 of therapy (P = 0.011). In addition, at day 3, fungicidal activity against blastoconidia of Candida albicans was enhanced by M-CSF treatment (P = 0.026), whereas antifungal activity against hyphae of Aspergillus fumigatus was not significantly changed. Bactericidal activity against Staphylococcus aureus was increased at day 3 (P = 0.004). By Northern blot analysis, M-CSF does not upregulate the expression of components of the NADPH-oxidase, the multicomponent enzyme system responsible for generation of superoxide radicals by monocytes. Instead, the predominant effect of M-CSF on circulating monocytes is probably a post-transcriptional effect. In conclusion, these findings suggest that administration of M-CSF to patients may enhance microbicidal activities and thus may provide a useful adjunct to conventional antimicrobial therapy.

    View details for Web of Science ID A1996TT98200006

    View details for PubMedID 8742065

Stanford Medicine Resources:

Footer Links: